Safety and Feasibility Study of Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 14 Mar 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Axicabtagene ciloleucel (Primary)
Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma
Focus Therapeutic Use

14 Nov 2023 Planned primary completion date changed from 31 Dec 2023 to 31 Jan 2024.
14 Nov 2023 Status changed from recruiting to active, no longer recruiting.
21 Jan 2022 Exclusion criteria of patients with history of symptomatic deep vein thrombosis or pulmonary embolism requiring systemic anticoagulation within 6 months of enrolment changed to within 3 months of enrolment. "Line related DVT that is treated is not exclusionary" newly added in exclusion.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com